Glybuthiazole is a sulfonamide derivative with antihyperglycemic activity, which possesses anti-diabetic properties. It is able to lower blood glucose levels by increasing the release of insulin from pancreatic beta cells.

Glenvastatin (HR780) is a synthetic HMG-CoA reductase (HMGCR) inhibitor. Like other statins, glenvastatin shows very low systemic bioavailability due to an extensive first pass effect at the intestinal and/or hepatic level. This is a positive trait, since the liver is the target organ for statins. Evidence has been found that glenvastatin protects the vascular endothelium from oxidant stress and inhibits the migration and proliferation of smooth muscle cells. In rabbits, long-term treatment with glenvastatin reduces the plasma cholesterol level, and decreases the liver cholesterol contents. There are no results of clinical trials for glenvastatin.

Draquinolol is a cardioselective beta-adrenoceptor antagonist with a long duration of action in vivo. The long duration of action of draquinolol in vivo is due to the formation of a tight complex with beta 1-adrenoceptors. Draquinolol reduced an exercise tachycardia.

Orestrate was developed as an estrogenic steroid that has never been marketed.

Estrapronicate is a synthetic estrogen exerting anabolic properties.

Quinezamide is a pyrazolo[1,5-c]quinazoline derivative patented by E. Gy. T. Gyogyszervegyeszeti Gyar, Hung as antiulcerogenic compound.

Tamethicillin is a basic ester pro-drug of methicillin (MET) which is converted in the body by non-specific esterases to MET. Tamethicillin was used as an antibacterial agent in the veterinary as a useful alternative for the treatment of mastitis in livestock, especially in mastitis due to beta-lactamase-producing Staphylococcus.

Glicondamide is a derivative of sulphonamides (antibacterial sulfa drugs). It acts by increasing the release of insulin from pancreatic beta cells, resulting in lower blood glucose levels.

Brefonalol also known as BDF 8186, a beta-adrenergic blocking agent with vasodilating properties. This drug was being developed for the treatment of hypertension, arrhythmias and angina pectoris. However, these studies were discontinued.

ISOXAPROLOL is a potent beta-adrenoceptor antagonist with antihypertensive properties. It was effective in lowering blood pressure in acute trials on spontaneously hypertensive rats at a dosage of 15 mg/kg.